The most imminent catalyst at the moment is the shares bought by the hedge fund Sarissa Capital Management LP. They acquired a 6.2% stake in the company which is facing a downward trend in the share prices. This purchase may help the stock prices to recover slightly, if not substantially.
The trial data from the gastrointestinal stromal tumors (GIST) study is expected in early 2014. The data would then allow the company to decide which direction to take with the GIST trials. This could prove to be an important catalyst if the results are positive.
ARIAD is keen to roll out Iclusig in Europe over the next few months. Further, it is looking for assessment approval by the regulatory authorities in Switzerland by the end of 2013. The company also has plans to file the drug in Australia and Canada, and expecting approvals in the first half of 2014. After the data is obtained from the ongoing clinical trials in Japan, ARIAD expects to file for the drug in Japan in the second half of 2014. These events will result in a cash inflow for the company and may prove to be positive catalysts for the share prices.
Most likely will happen but in the end judge decides, not company. Potentially more can happen between now an emergence.